Cancer treatment and research communications最新文献

{"title":"Assessing the role of MSH2 and MSH6 gene expression deficiency in prostate cancer progression, a cross-sectional study","authors":"Fatemeh Sharbati,&nbsp;Hedieh Moradi Tabriz,&nbsp;Elham Nazar","doi":"10.1016/j.ctarc.2024.100826","DOIUrl":"10.1016/j.ctarc.2024.100826","url":null,"abstract":"<div><h3>Background</h3><p>Recently, some evidence emphasized the value of MSH2 and MSH6 inactivation and their hypermutation in predicting different cancers. The present consideration is to evaluate the value of MSH2 and MSH6 protein deficient studied by the immunohistochemistry (IHC) method and the tumor behaviors and aggressiveness in prostatic carcinoma.</p></div><div><h3>Methods</h3><p>This cross-sectional study was performed on 80 examples extricated from patients who endured prostate cancer and were planned for radical prostatectomy surgery. The expression levels of the genes were studied by IHC staining.</p></div><div><h3>Results</h3><p>The deficiency in MSH2 and MSH6 expression was revealed in 10.0 % and 11.3 % of patients respectively, while the reduction of simultaneous expression in two genes was found in 6.2 % of patients. In the two subgroups with and without MSH2 and/or MSH6 staining, there was no difference in patients' mean age and history of prostate cancer. There was also no difference in tumor-related behaviors including combined Gleason grade group, tumor stage, vascular invasion, perineural invasion, and prostatic capsular invasion between the groups with and without gene loss.</p></div><div><h3>Conclusion</h3><p>The evaluation of the deficient rate of two genes among patients with prostate cancer to predict the tumor grade and its aggressive behavior needs further study in every population.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000388/pdfft?md5=fed1219763129e48f95540243616817c&pid=1-s2.0-S2468294224000388-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141316796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate cancer knowledge and barriers to screening among men at risk in northern Tanzania: A community-based study","authors":"Bartholomeo Nicholaus Ngowi ,&nbsp;Alex Mremi ,&nbsp;Orgeness Jasper Mbwambo ,&nbsp;Modesta Paschal Mitao ,&nbsp;Mramba Nyindo ,&nbsp;Kien Alfred Mteta ,&nbsp;Blandina Theophil Mmbaga","doi":"10.1016/j.ctarc.2024.100811","DOIUrl":"https://doi.org/10.1016/j.ctarc.2024.100811","url":null,"abstract":"<div><h3>Background</h3><p>Although prostate cancer (Pca) screening plays important role in early diagnosis and reduction of mortality, Tanzanian men are relatively unscreened. We aimed to investigate Pca knowledge level and barriers to screening among at-risk men in northern Tanzania.</p></div><div><h3>Methods</h3><p>This community-based survey was conducted in northern Tanzania from May to September 2022, involving men age ≥40 years. Participants were invited by announcing in local churches, mosques, brochures, and social media groups. Participants attended a nearby health facility where survey questionnaires were administered. Knowledge level was measured on the Likert scale and scored as poor (&lt;50 %) or good (≥50 %).</p></div><div><h3>Results</h3><p>A total of 6205 men with a mean age of 60.23 ± 10.98 years were enrolled in the study. Of these, 586 (9.5 %) had ever been screened for Pca. Overall, 1263 men (20.4 %) had good knowledge of Pca. Having health insurance, knowing at least 1 risk factor or symptoms of Pca, and hospital as the source of Pca information were significantly associated with ever being screened. The most common reasons for not being screened were a belief that they are healthy (<em>n</em> = 2983; 53.1 %), that Pca is not a serious disease (<em>n</em> = 3908; 69.6 %), and that digital rectal examination (DRE) as an embarrassing (<em>n</em> = 3634; 64.7 %) or harmful (<em>n</em> = 3047; 54.3 %) procedure.</p></div><div><h3>Conclusion</h3><p>Having Pca knowledge, health insurance and hospital source of information were correlated with increased screening. False beliefs about DRE and the seriousness of Pca had negative effects on screening. Increasing community knowledge and universal health coverage would improve uptake of Pca screening.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000236/pdfft?md5=278085955eb28f5b88051eb990ce9c00&pid=1-s2.0-S2468294224000236-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140341213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The real-world insights on the use, safety, and outcome of immune-checkpoint inhibitors in underrepresented populations with lung cancer","authors":"","doi":"10.1016/j.ctarc.2024.100833","DOIUrl":"10.1016/j.ctarc.2024.100833","url":null,"abstract":"<div><h3>Background</h3><p>The data on immune checkpoint inhibitors (ICI) use in lung cancer individuals generally underrepresented in clinical trials are limited. We aimed to examine the ICI access, safety, and outcome in these populations using real-world data.</p></div><div><h3>Methods</h3><p>Patients with lung cancer newly started on ICIs from 2018 to 2021 were included. Patient factors (age, sex, race, insurance, Charlson comorbidity index (CCI), Eastern Cooperative Oncology Group (ECOG) performance status, histories of autoimmune disease (AD), infection within 3 months before treatment, and brain metastasis) were collected and grouped. Associations of each patient factor with the time-to-treatment initiation (TTI) of ICIs and immune-related adverse events (irAEs) were examined via cumulative incidence analyses and Chi-squared tests, respectively. Log-rank tests and Cox models were used to assess association of patient factors with overall survival (OS).</p></div><div><h3>Results</h3><p>Of 125 patients (median age:70 years (50–88), 68 (54.4 %) males), 9 (7.2 %) had Medicaid/uninsured, 44 (35.2 %) had ECOG ≥ 2, 101 (80.8 %) had CCI ≥ 3, 16 (12.8 %) had ADs, 14 (11.2 %) had infections, and 26 (20.8 %) had brain metastases. In newly diagnosed stage IV patients (<em>N</em> = 62), no difference in TTI was found by patient factors. Fifty irAEs occurred within 12 months and no differences in irAEs occurrence by patient factors. In advanced-stage group (<em>N</em> = 123), OS did not differ by patient factors, except for race (<em>p</em> = 0.045). Whites showed an inferior OS than non-Whites in multivariable regression. (Hazards ratio = 2.82 [1.01–7.87], <em>p</em> = 0.047).</p></div><div><h3>Conclusions</h3><p>Previously poorly represented subgroups were shown to have no significant delays in ICI use, general tolerance, and comparable outcomes. This adds practical evidence to ICI use in clinically and/or socio-demographically marginalized populations.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000455/pdfft?md5=d6e48f89684fa10847abbc2cc41ad10b&pid=1-s2.0-S2468294224000455-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141622993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of large amino acid transporter type 1 (LAT1) expression in pulmonary adenocarcinoma: A tissue microarray study","authors":"Azusa Terao ,&nbsp;Hironori Ninomiya ,&nbsp;Kengo Takeuchi","doi":"10.1016/j.ctarc.2024.100814","DOIUrl":"https://doi.org/10.1016/j.ctarc.2024.100814","url":null,"abstract":"<div><h3>Background</h3><p>Large amino acid transporter type 1 (LAT1) provides cancer cells with essential amino acids for both protein synthesis and cell growth and may predict patient prognosis. Additionally, LAT1 inhibition can be a therapeutic target. This study aimed to examine the prognostic significance of LAT1 expression in lung cancer, paying special attention to adenocarcinoma subtypes.</p></div><div><h3>Methods</h3><p>Tissue microarrays (TMA) of 1,560 total cores obtained from surgically resected lung cancer specimens between 1995 and 2008 at our hospital were used. Overall, 795 cases of adenocarcinoma were identified, and 717 underwent further evaluation. Immunohistochemical staining of whole slides and TMA cores were assessed to set H-score cutoff value.. Immunohistochemical expression of LAT1 was examined based on the subtypes of adenocarcinoma. Statistical analyses explored the prognostic significance of LAT1.</p></div><div><h3>Results</h3><p>Adenocarcinoma accounted for 71.8% of all cases (<em>n</em> = 795), and 216 cases (27.1%) expressed LAT1. The 795 cases were categorized into five subtypes: lepidic (<em>n</em> = 29, 3.6%), papillary (<em>n</em> = 601, 75.6%), acinar (<em>n</em> = 58, 7.3%), and solid (<em>n</em> = 9, 1.1%); 717 of the 795 cases were further assessed according to the exclusion criteria. The LAT1-positive ratio increased as the architectural grade increased. Notably, in papillary adenocarcinoma, the LAT1-positive group had significantly lower overall survival compared to the negative group (10-year survival: 45.6% vs. 60.8%, <em>p</em> &lt; 0.001).</p></div><div><h3>Conclusion</h3><p>LAT1 expression was higher in high-grade subtypes of pulmonary adenocarcinoma. Moreover, LAT1 expression is useful for predicting prognosis, particularly in papillary adenocarcinoma, facilitating prognostic stratification of papillary adenocarcinoma.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000261/pdfft?md5=35ae997d2b2534a82c44ea8bb7694380&pid=1-s2.0-S2468294224000261-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140650023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Programmed death ligand-1 (PD-L1) clone 22C3 expression in resected colorectal cancer as companion diagnostics for immune checkpoint inhibitor therapy: A comparison study and inter-rater agreement evaluation across proposed cut-offs and predictive (TPS, CPS and IC) scores","authors":"Dordi Lea ,&nbsp;Claudia Zaharia ,&nbsp;Kjetil Søreide","doi":"10.1016/j.ctarc.2023.100788","DOIUrl":"10.1016/j.ctarc.2023.100788","url":null,"abstract":"<div><h3>Background</h3><p>Expression of programmed death ligand-1 (PD-L1) guides the use of immune checkpoint inhibitors (ICI) in several cancers. In colorectal cancer (CRC), ICI are only approved for metastatic CRC, while several studies suggest high efficacy even in operable CRC. The aim of this study was to investigate the inter-rater agreement of PD-L1 as a companion diagnostic marker.</p></div><div><h3>Methods</h3><p>Specimens from resected stage I-III CRC (<em>n</em> = 166 tumors) were stained with PD-L1 22C3 clone. PD-L1 expression was scored by two pathologists as tumor proportion score (TPS), combined positive score (CPS) and immune cell score (IC). Inter-rater agreement was tested using three different agreement coefficients.</p></div><div><h3>Results</h3><p>Raw scores of the two pathologists had ‘good’ to ‘excellent’ correlation. Spearman's rho for TPS=0.917 (95 %CI 0.839–0.995), for CPS=0.776 (95 %CI 0.726–0.826) and IC=0.818 (95 %CI 0.761–0.875). For TPS, kappa (κ)-agreements for both the ≥1 % and ≥10 % cutoffs had excellent correlation. For CPS the ≥1 % and ≥10 % cutoffs demonstrated κ=0.32 (95 %CI 0.12–0.51) and κ=0.36 (95 %CI 0.25–0.48) respectively. Cutoffs for IC showed κ=0.53 (95 %CI 0.18–0.79) for the ≥1 % cutoff, and κ=0.61 (95 %CI 0.48–0.73) for the ≥10 % cutoff. Gwet's agreement coefficient (AC₁) showed higher agreement coefficients than κ-values for most, but not all cut-offs.</p></div><div><h3>Conclusion</h3><p>Agreement for PD-L1 was good to excellent for raw scores. Agreement variation across several criteria and cut-offs suggests the need for more robust criteria for PD-L1 as a companion diagnostic marker.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294223001107/pdfft?md5=593655e3a8465d86b040cf837d710a6c&pid=1-s2.0-S2468294223001107-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139015329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Porcine-human glioma xenograft model. Immunosuppression and model reproducibility","authors":"P.Jack Hoopes ,&nbsp;Armin D. Tavakkoli ,&nbsp;Karen A. Moodie ,&nbsp;Kirk J. Maurer ,&nbsp;Kenneth R. Meehan ,&nbsp;Diana J. Wallin ,&nbsp;Ethan Aulwes ,&nbsp;Kayla E.A. Duval ,&nbsp;Kristen L. Chen ,&nbsp;Margaret A.Crary -Burney ,&nbsp;Chen Li ,&nbsp;Xiaoyao Fan ,&nbsp;Linton T. Evans ,&nbsp;Keith D. Paulsen","doi":"10.1016/j.ctarc.2024.100789","DOIUrl":"10.1016/j.ctarc.2024.100789","url":null,"abstract":"<div><h3>Background</h3><p>Glioblastoma is the most common primary malignant and treatment-resistant human brain tumor. Rodent models have played an important role in understanding brain cancer biology and treatment. However, due to their small cranium and tumor volume mismatch, relative to human disease, they have been less useful for translational studies. Therefore, development of a consistent and simple large animal glioma xenograft model would have significant translational benefits.</p></div><div><h3>Methods</h3><p>Immunosuppression was induced in twelve standard Yucatan minipigs. 3 pigs received cyclosporine only, while 9 pigs received a combined regimen including cyclosporine (55 mg/kg q12 h), prednisone (25 mg, q24 h) and mycophenolate (500 mg q24 h). U87 cells (2 × 10⁶) were stereotactically implanted into the left frontal cortex. The implanted brains were imaged by MRI for monitoring. In a separate study, tumors were grown in 5 additional pigs using the combined regimen, and pigs underwent tumor resection with intra-operative image updating to determine if the xenograft model could accurately capture the spatial tumor resection challenges seen in humans.</p></div><div><h3>Results</h3><p>Tumors were successfully implanted and grown in 11 pigs. One animal in cyclosporine only group failed to show clinical tumor growth. Clinical tumor growth, assessed by MRI, progressed slowly over the first 10 days, then rapidly over the next 10 days. The average tumor growth latency period was 20 days. Animals were monitored twice daily and detailed records were kept throughout the experimental period. Pigs were sacrificed humanely when the tumor reached 1 - 2 cm. Some pigs experienced decreased appetite and activity, however none required premature euthanasia. In the image updating study, all five pigs demonstrated brain shift after craniotomy, consistent with what is observed in humans. Intraoperative image updating was able to accurately capture and correct for this shift in all five pigs.</p></div><div><h3>Conclusion</h3><p>This report demonstrates the development and use of a human intracranial glioma model in an immunosuppressed, but nongenetically modified pig. While the immunosuppression of the model may limit its utility in certain studies, the model does overcome several limitations of small animal or genetically modified models. For instance, we demonstrate use of this model for guiding surgical resection with intraoperative image-updating technologies. We further report use of a surrogate extracranial tumor that indicates growth of the intracranial tumor, allowing for relative growth assessment without radiological imaging.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000017/pdfft?md5=df2ee3f756683a1748cb62c71a7c45ce&pid=1-s2.0-S2468294224000017-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139541924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Finding the PSA-based screening stopping age using prostate cancer risk","authors":"Azin Nahvijou ,&nbsp;Mohammad Hadian ,&nbsp;Naser Mohamadkhani","doi":"10.1016/j.ctarc.2024.100791","DOIUrl":"10.1016/j.ctarc.2024.100791","url":null,"abstract":"<div><h3>Background</h3><p>Prostate Cancer screening was not rational for people who were suffered from other serious diseases and had a low quality of life. Biopsy and Prostate-Specific Antigen based screening also had imperfect information, pain, and costs. Finding the Prostate Cancer screening stopping age was important because after an age, Prostate-Specific Antigen test was not recommended and patients should not perform subsequent procedures. It could reduce the economic burden of Prostate Cancer. In this study, we modeled the effects of Prostate Cancer risk and comorbidities on the Prostate Cancer screening stopping age.</p></div><div><h3>Methods</h3><p>first, using a Markov model for PC progression, we provided a model for optimal Prostate Cancer screening stopping age. Second, we explored the relationship between comorbidities effects, Prostate Cancer risk and the stopping age.</p></div><div><h3>Results</h3><p>Our results suggest that the stopping age was an increasing function of PC risk and comorbidities effects. Screening should be stopped before 70 years. Finding showed that for men with diseases such as stroke or heart diseases, screening should not be performed at any age.</p></div><div><h3>Conclusions</h3><p>Personalizing PC screening through paying more attention to PC risk can improve efficiency of screening. The role of personal characteristics such as race, family history, and previous PSA in PC screening decision-making was highlighted by stratifying men in different PC risk groups to find their stopping age. Incorporating comorbidity effects shows that severity of comorbidity was a crucial factor in PC screening stopping age decision-making process.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000030/pdfft?md5=56341976e6a2415345e2af1a72f52e23&pid=1-s2.0-S2468294224000030-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139545815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of sentinel lymph node biopsy and bilateral pelvic nodal dissection using methylene blue dye in early-stage operable cervical cancer—A prospective study","authors":"Vijaya Lakshmi Vemula Venkata ,&nbsp;Narendra Hulikal ,&nbsp;Amit Kumar Chowhan","doi":"10.1016/j.ctarc.2024.100816","DOIUrl":"https://doi.org/10.1016/j.ctarc.2024.100816","url":null,"abstract":"<div><h3>Objective</h3><p>To evaluate the effectiveness of methylene blue dye in detecting sentinel lymph nodes (SLNs) in women with early-stage operable (defined as FIGO I-IIA) cervical cancer. It also aims to evaluate procedural challenges and accuracy.</p></div><div><h3>Method</h3><p>This prospective study, which focused on 20 women with early-stage cervical cancer, was carried out between June 2016 and December 2017. These patients had SLN mapping with methylene blue dye injections and thorough examinations, including imaging. All patients underwent radical hysterectomy and complete bilateral pelvic lymphadenectomy. No additional investigation was done on the lymph node in cases where a metastasis was found in the first H&amp;E-stained segment of the sentinel node.</p></div><div><h3>Result</h3><p>20 patients were included in the analysis. The median age of the subjects was 53, and 95 % of them had squamous cell carcinoma. 90 % of the time, the identification of SLNs was effective, and 55 SLNs were found, of which 52.7 % were on the right side of the pelvis and 47.3 % on the left. The obturator group had the most nodes, followed by the external and internal iliac groups in descending order of occurrence. Metastasis was detected in 3 patients, resulting in a sensitivity of 100 % and a specificity of 93.75 % for SLN biopsy. Notably, no false-negative SLNs were found. Complications related to methylene blue usage included urine discoloration in 30 % of patients.</p></div><div><h3>Conclusion</h3><p>This trial highlights the promising efficacy and safety of methylene blue dye alone for SLN identification in early-stage operable cervical cancer, with a notably higher success rate. Despite limitations like a small sample size, healthcare professionals and researchers can build upon the insights from this study to enhance cervical cancer management.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000285/pdfft?md5=32abd5744810eab1d50c7068a59119c2&pid=1-s2.0-S2468294224000285-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140843932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of the association between the CASP8rs1045485 and SOD2 rs4880 single nucleotide polymorphisms (SNPs) with breast cancer","authors":"","doi":"10.1016/j.ctarc.2024.100835","DOIUrl":"10.1016/j.ctarc.2024.100835","url":null,"abstract":"<div><h3>Introduction</h3><p>Single nucleotide polymorphisms (SNPs) have been identified as prognostic markers that can influence the response to chemotherapy and, ultimately, the outcome of the disease. The objective of this study is to investigate the association between the rs1045485 and rs4880 variants and breast cancer.</p></div><div><h3>Methods</h3><p>Ninety-nine cases and 81 healthy individuals (over 60 years old) were recruited from Iranian population. Genotyping of the rs1045485 and rs4880 polymorphisms was determined using the PCR-RFLP molecular method. The obtained results were then evaluated using the SPSS 23.0, odds ratios (ORs) with 95 % confidence intervals (95 %CIs).</p></div><div><h3>Results</h3><p>The average age of the subjects was 50.17± 1.8 years, with age ranging from 40 to 76 years. Additionally, more patients were in stage and grade 2 of the disease. Furthermore, 51.73 %, 53.24 % and 41.48 % of patients tested positive for ER, PR and HER2 status, respectively. The odds ratios of the genotypes studied for each of the two variants were not statistically significant. Additionally, all models (dominant, codominant, recessive and over dominant) also indicated that this difference was not significant (<em>p</em> &gt; 0.05). Investigation of the association between the <em>CASP8</em>rs1045485 and <em>SOD2</em> rs4880 variants with clinicopathological status were not revealed a significant relationship. The Hardy-Weinberg test showed that the evaluated population was balanced (<em>p</em> &gt; 0.05).</p></div><div><h3>Conclusion</h3><p>In the studied models of both polymorphisms, no significant correlation was found between the genotypes and the conditions of estrogen, progesterone and Her2 receptors, as well as the stage and grade of the disease.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000479/pdfft?md5=28204bba0ca17932a994555216733672&pid=1-s2.0-S2468294224000479-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141703525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Warfarin intake in relation to diagnosis reduces mortality in patients with colorectal cancer – a register-based study","authors":"Anders S. Eriksson ,&nbsp;Henry Eriksson ,&nbsp;Per-Olof Hansson ,&nbsp;Kurt Svärdsudd","doi":"10.1016/j.ctarc.2024.100820","DOIUrl":"10.1016/j.ctarc.2024.100820","url":null,"abstract":"<div><h3>Background</h3><p>Several studies have analyzed the effect of anticoagulants on cancer survival, with varying results. This study aimed to assess the effect of warfarin on survival in patients with colorectal cancer (CRC) in relation to timing of warfarin initiation.</p></div><div><h3>Methods</h3><p>Data on 10,051 individuals aged ≥45 years in the Västra Götaland Region of Sweden, and diagnosed with CRC between 2000 and 2009, were obtained from the Swedish National Cancer Register. Those who received warfarin treatment (<em>n</em>= 1,216) during the study period were labeled cases and those who did not (<em>n</em>= 8,873) were labeled controls. For statistical analysis, National Cancer Register data were merged with mortality data from the Swedish National Cause of Death register and data from the regional warfarin treatment register.</p></div><div><h3>Results</h3><p>Hazard rates for CRC-specific mortality were lower in cases than in controls. When warfarin was used for any reason at any time, cases had a significantly lower CRC-specific mortality than controls among both women (hazard ratio [HR] 0.71; 95 % confidence interval [CI] 0.59–0.85; <em>p</em>= 0.0002) and men (HR 0.61; 95 % CI 0.52–0.72; <em>p</em> &lt; 0001). Warfarin treatment after CRC diagnosis reduced CRC-specific mortality by 80 %; however, when warfarin was given before or ≥5 years after diagnosis, CRC-specific mortality did not significantly decrease. The number needed to treat to avoid one death was four.</p></div><div><h3>Conclusion</h3><p>Use of warfarin early after diagnosis in patients with CRC was associated with improved survival.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468294224000327/pdfft?md5=dcb36b9fef1eb26c354c6a7eed173534&pid=1-s2.0-S2468294224000327-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140956574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}